Long-Term Effectiveness and Safety of Omalizumab in a Pediatric Patient With Severe Persistent Asthma: A Case Report

Abstract

Abstract Omalizumab has emerged as a promising treatment option for severe persistent allergic asthma in children aged 6 years and older whose symptoms do not improve after conventional therapy with inhaled corticosteroids and long-acting beta-agonists. Omalizumab has been shown to reduce asthma exacerbations, improve lung function, and reduce the need for oral corticosteroids. However, clinical evidence regarding the long-term efficacy and safety of omalizumab in pediatric patients with severe persistent asthma is limited. In this report, we discuss the long-term effectiveness and safety of omalizumab in a pediatric patient with severe persistent asthma. Our objective is to highlight the potential benefits and risks of long-term use of omalizumab in pediatric patients with asthma.